Human medicines European public assessment report (EPAR): Halaven, eribulin, Breast Neoplasms,Liposarcoma, Date of authorisation: 17/03/2011, Revision: 20, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996b1 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Ecansya (previously Capecitabine Krka), capecitabine, Colonic Neoplasms,Breast Neoplasms,Colorectal Neoplasms,Stomach Neoplasms, Date of authorisation: 19/04/2012, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996c4 ◽

2018 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Colorectal Neoplasms ◽

Stomach Neoplasms ◽

Colonic Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Carcinoma, Renal Cell,Peritoneal Neoplasms,Ovarian Neoplasms,Breast Neoplasms,Carcinoma, Non-Small-Cell Lung,Fallopian Tube Neoplasms, Date of authorisation: 14/01/2018, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-4e9a82 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Small Cell Lung ◽

Assessment Report ◽

Peritoneal Neoplasms ◽

European Public ◽

European Public Assessment Report ◽

Fallopian Tube Neoplasms ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Breast Neoplasms, Date of authorisation: 20/06/2019, Status: Authorised

Case Medical Research ◽

10.31525/cmr-172b113 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Stomach Neoplasms,Breast Neoplasms, Date of authorisation: 08/02/2018, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-39966a ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Stomach Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Breast Neoplasms,Pancreatic Neoplasms,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 10/01/2008, Revision: 24, Status: Authorised

Case Medical Research ◽

10.31525/cmr-15997e6 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Pancreatic Neoplasms ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Doxolipad, doxorubicin, Breast Neoplasms,Ovarian Neoplasms, Date of refusal: 08/08/2019, Status: Refused

Case Medical Research ◽

10.31525/cmr-1b3641e ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Taxespira (previously Docetaxel Hospira UK Limited ), docetaxel, Stomach Neoplasms,Prostatic Neoplasms,Breast Neoplasms,Head and Neck Neoplasms,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 28/08/2015, Revision: 8, Status: Withdrawn

Case Medical Research ◽

10.31525/cmr-1f52484 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Head And Neck ◽

Prostatic Neoplasms ◽

Stomach Neoplasms ◽

Head And Neck Neoplasms ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Iasibon, ibandronic acid, Hypercalcemia,Fractures, Bone,Neoplasm Metastasis,Breast Neoplasms, Date of authorisation: 21/01/2011, Revision: 8, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1250c37 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Neoplasm Metastasis ◽

Bone Neoplasm ◽

Ibandronic Acid ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Stomach Neoplasms,Breast Neoplasms, Date of authorisation: 26/07/2018, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-12154e1 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Stomach Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Breast Neoplasms, Date of authorisation: 09/03/2004, Revision: 20, Status: Authorised

Case Medical Research ◽

10.31525/cmr-59961c ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text